Earnings History Data for CASI Pharmaceuticals, Inc. (CASI) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14-05-2024 | PM | CASI | CASI Pharmaceuticals Inc. | 36.00 | -0.71 | -0.05 | 0.00 | CASI Pharmaceuticals GAAP EPS of -$0.71, revenue of $3.4M [5/14/2024 10:43 AM] |
3.15 | 0.58 (22.73%) |
2.30 | -0.26 (-10.33%) |
1.85 - 8.48 | 51,807 | 10,000 | 530 | ||
| 28-03-2024 | PM | CASI | CASI Pharmaceuticals Inc. | 40.00 | -0.29 | -0.24 | 0.00 | CASI Pharmaceuticals GAAP EPS of -$2.02, revenue of $33.88M [3/28/2024 7:22 AM] |
3.59 | 0.59 (19.67%) |
2.87 | -0.13 (-4.38%) |
1.71 - 8.48 | 121,146 | 90,000 | 801 | ||
| 14-11-2023 | PM | CASI | CASI Pharmaceuticals Inc. | 0.00 | -0.35 | -0.56 | 0.00 | CASI Pharmaceuticals GAAP EPS of -$0.35, revenue of $8.84M [11/14/2023 7:34 AM] |
4.41 | -0.04 (-0.96%) |
4.20 | -0.25 (-5.62%) |
1.45 - 4.99 | 40,497 | 60,000 | 151 | ||
| 11-08-2023 | PM | CASI | CASI Pharmaceuticals Inc. | 0.00 | -0.77 | -0.50 | 0.00 | CASI Pharmaceuticals GAAP EPS of -$0.77, revenue of $9.82M [8/11/2023 7:45 AM] |
2.27 | 0.02 (0.89%) |
2.35 | 0.06 (2.62%) |
1.45 - 4.86 | 3,142 | 20,000 | 0 | ||
| 17-05-2023 | PM | CASI | CASI Pharmaceuticals Inc. | 0.00 | -0.45 | -0.64 | 0.00 | CASI Pharmaceuticals GAAP EPS of -$0.45, revenue of $8.35M [5/17/2023 8:06 AM] |
2.31 | -0.19 (-7.48%) |
0.0 | 0.0 (0.00%) |
1.45 - 6.85 | 8,723 | 10,000 | 0 | ||
| 26-04-2023 | PM | 7:00 AM ET (Apr 26) |
CASI | CASI Pharmaceuticals Inc. | 0.00 | -1.44 | -0.61 | 0.00 | CASI Pharmaceuticals GAAP EPS of -$3.01 misses by $2.64, revenue of $43.12M beats by $32.31M [4/26/2023 1:30 PM] |
2.93 | -0.04 (-1.35%) |
0.0 | 0.0 (0.00%) |
1.45 - 6.85 | 5,375 | 30,000 | 0 | |
| 12-08-2022 | PM | 7:00 AM ET (Aug 12) |
CASI | CASI Pharmaceuticals, Inc. | 37.14 | -0.56 | -0.65 | -0.50 | CASI Pharmaceuticals GAAP EPS of -$0.56, revenue of $8.57M beats by $0.7M [8/12/2022 7:03 AM] |
3.47 | -0.43 (-11.03%) |
3.92 | 0.02 (0.51%) |
2.24 - 17.40 | 297,647 | 730,000 | 24,970 | |
|
||||||||||||||||||
| 12-05-2022 | PM | 7:00 AM ET (May 12) |
CASI | CASI Pharmaceuticals, Inc. | 49.59 | -0.06 | -0.10 | -0.11 | CASI Pharmaceuticals GAAP EPS of -$0.06 beats by $0.03, revenue of $9.06M misses by $0.18M [5/12/2022 7:20 AM] |
0.3121 | -0.02 (-5.92%) |
0.35 | 0.02 (5.51%) |
0.31 - 1.77 | 315,965 | 290,000 | 804 | |
|
||||||||||||||||||
| 28-03-2022 | PM | 7:00 AM ET (Mar 28) |
CASI | CASI Pharmaceuticals, Inc. | 115.58 | -0.04 | 0.00 | -0.12 | CASI Pharmaceuticals GAAP EPS of -$0.27 beats by $0.03, revenue of $30.17M beats by $0.09M [3/28/2022 7:09 AM] |
0.91 | 0.06 (7.02%) |
0.85 | 0.0 (-0.04%) |
0.56 - 2.42 | 351,511 | 410,000 | 7,025 | |
| 12-11-2021 | PM | 7:00 AM ET (Nov 12) |
CASI | CASI Pharmaceuticals, Inc. | 148.19 | -0.07 | -0.05 | -0.14 | CASI Pharmaceuticals EPS misses by $0.01, beats on revenue [11/12/2021 7:04 AM] |
1.07 | 0.02 (1.90%) |
1.06 | 0.01 (0.95%) |
1.03 - 3.90 | 1,647,537 | 1,140,000 | 78,875 | |
| 12-08-2021 | PM | 7:00 AM ET (Aug 12) |
CASI | CASI Pharmaceuticals, Inc. | 162.17 | -0.05 | -0.09 | -0.07 | CASI Pharmaceuticals EPS beats by $0.02, beats on revenue [8/12/2021 7:22 AM] |
1.16 | -0.02 (-1.69%) |
1.20 | 0.02 (1.69%) |
1.14 - 3.90 | 1,537,251 | 350,000 | 122,518 | |
| 13-05-2021 | PM | 7:00 AM ET (May 13) |
CASI | Casi Pharmaceuticals, Inc. | 200.00 | -0.11 | -0.05 | 0.00 | CASI Pharmaceuticals EPS misses by $0.05, beats on revenue [5/13/2021 7:10 AM] |
1.42 | -0.03 (-2.07%) |
1.51 | 0.06 (4.14%) |
1.32 - 3.90 | 2,176,043 | 1,930,000 | 24,919 | |
| 30-03-2021 | PM | 7:00 AM ET (Mar 30) |
CASI | CASI Pharmaceuticals, Inc. | 241.69 | -0.12 | -0.07 | -0.13 | CASI Pharmaceuticals EPS misses by $0.06, beats on revenue [3/30/2021 7:33 AM] |
1.98 | 0.0 (0.00%) |
1.95 | -0.03 (-1.52%) |
1.46 - 3.90 | 2,284,994 | 1,470,000 | 75,139 | |
| 09-11-2020 | PM | After the close (Nov 9) |
CASI | CASI Pharmaceuticals, Inc. | 246.65 | -0.14 | -0.05 | -0.10 | CASI Pharmaceuticals EPS misses by $0.08, beats on revenue [11/9/2020 7:14 AM] |
1.93 | 0.01 (0.52%) |
2.10 | 0.18 (9.38%) |
1.15 - 3.57 | 347,587 | 895,117 | 3,438 | |
|
|
||||||||||||||||||
| 10-08-2020 | PM | After the close (Aug 10) |
CASI | CASI Pharmaceuticals, Inc. | 235.49 | -0.07 | -0.08 | -0.10 | CASI Pharmaceuticals EPS misses by $0.01, misses on revenue [8/10/2020 7:10 AM] |
1.96 | 0.04 (2.36%) |
1.89 | -0.02 (-1.05%) |
1.15 - 3.82 | 575,733 | 774,551 | 15,142 | |
|
|
||||||||||||||||||